CRISPR Therapeutics AG

CRSPintermediary

CRISPR Therapeutics made history with the first FDA-approved CRISPR gene-editing therapy, Casgevy, for sickle cell disease. Co-founded by Nobel laureate Emmanuelle Charpentier, the company is leveraging its gene-editing platform across hematology, oncology (allogeneic CAR-T), and in vivo applications to create potentially curative one-time treatments.

⇄ Compare

Produkte & Umsatz

Umsatzanteil nach Produkt

Umsatzaufschlüsselung ($0.4B)

Statische Daten (Echtzeitfinanzen werden geladen…)

Casgevy Product Revenue (50%)

Collaboration Revenue (Vertex) (35%)

Grants & Other (15%)

Segmentzusammensetzung und Hauptkunden

Produktdetails

Casgevy (Exagamglogene)50%

First CRISPR-based gene therapy approved for sickle cell disease and beta-thalassemia

CTX110 / Allogeneic CAR-T25%

Off-the-shelf CRISPR-edited CAR-T cell therapies for blood cancers

In Vivo Gene Editing25%

Next-gen lipid nanoparticle-delivered CRISPR for liver and other organs

Lieferkettenbeziehungen

Wettbewerber

Regeneron Pharmaceuticals

Gene editing and genomic medicine

Auswirkung: Competing modalities

Moderna, Inc.

Gene therapy delivery platforms

Auswirkung: Competing therapeutic platforms

Partner

Alnylam Pharmaceuticals, Inc.

Complementary genetic medicine approaches

Auswirkung: Potential future collaboration

Makro- und Marktkontext

제약 / 바이오Sektornachrichten

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Nächste Katalysatoren

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Aktuelle Nachrichten

Nachrichten laden...

KI-Analyse

Klicken Sie auf "KI-Analyse abrufen" für eine KI-gestützte Lieferkettenanalyse von CRISPR Therapeutics AG.

Unternehmensinformationen

Hauptsitz

Zug, Switzerland

Gegründet

2013

Mitarbeiter

1,400+

Website

crisprtx.com

Sektorübersicht — 제약 / 바이오

Sektornachrichten